


Healthcare Informatics: Creating Value and Defining Challenges

Paul Bleicher, MD, PhD Chief Medical Officer Humedica Boston MA

43345098543534353

The Information Environment: Healthcare and Life Sciences



Who Wants Data, and Why?


- Pharmaceutical, biotechnology, medical device companies
- Hospital and ambulatory provider organizations, and their physicians
- Government
- Financial services
- Payors
- Consumers
- Employers

Health Care Organizational Use of Data

- Quality Management
 - Outcomes
 - Staffing and Resources
 - Physician and care team accountability
 - Accreditation and Pay for Performance
 - JCAHO, PQRI, HEDIS, etc.
 - Compliance with care maps, order sets, etc.
- Patient Safety
 - Risk profiles
 - Medication and procedural errors
 - Sentinel events
- Resource and Cost Analysis
- Research and Hypothesis Generation



Healthcare Needs for Electronic Data



Source: PricewaterhouseCoopers survey.

Pharmaceutical/Biotech Uses for De-identified Data

- Clinical research
 - Observational research natural history, risk factors, epidemiology,
 - Registries tumors, devices, diseases
 - Feasibility and planning
 - Recruitment
 - Treatment effectiveness, pharmacoeconomics, pharmacogenomics
- Pharmacovigilance
 - Tracking adverse events
- Market research
 - Supporting formulary decisions / pharmacoeconomics
 - Hypothesis generation
 - Understanding physician prescribing behavior
 - Understanding consumer prescribing behavior
- Sales Tools
 - Targeting physicians, systems
 - Sales incentive modeling


5 © 2009 Humedica, Inc. All rights reserved.



Government Uses for De-identified Data

- Framework for reimbursement
 - Pay for performance
- Protecting public health
 - Many similar clinical research uses
 - Disease statistics, outcomes
 - Disease surveillance, bioterrorism surveillance
 - Drug approval and pharmacovigilance
- Quality and clinical effectiveness
 - Benchmarking and national standards
 - Comparative effectiveness research






Now EHR Adoption is Better Than Assumed

- The rate of EMR adoption has been increasing significantly over the past decade
 - Fueled by government incentives courtesy of American Recovery & Reinvestment Act (ARRA)
 - On average, government provides \$44,000 per physician to spur adoption

% of office-based physicians using any EMR system and projected 2010 use*



Adoption of any EMR system reached 74.3% among offices with more than 11 physicians.**


* Source: CDC/ NCHS, National Ambulatory Medical Care Survey **Source: Electronic Medical Record Use by Office-based Physicians and Their Practices: United States, 2007

© 2009 Humedica, Inc. All rights reserved.

However, EHR Market is <u>still</u> a Hurdle to Secondary Data

- Hundreds of vendors and platforms
- Fragmented market with different needs/solutions for each
 - Solo practices, group practices, hospital systems, independent delivery networks (hospital c/w group practices)
- Many legacy systems use older technology
 - Older languages, hierarchical databases
- Much of the data isn't structured for statistical analysis
 - Images of transcribed dictations, etc.
- In many systems newer technology (XML, web services, etc.) is very low priority for implementation
- HL-7 may be available, but isn't used in many implementations
- Local customization makes data normalization very difficult
 9 © 2009 Humedica, Inc. All rights reserved.

The Pyramid of Value






11

Healthcare Data Warehousing: Areas of Concern

243345098543534353

Danger in Data Mining



12 © 2009 Humedica, Inc. All rights reserved.

Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.

- --- Archimedes
- Sample of 5M people
 - 80% power to detect a statistical difference between
 - 19.9% and 20% readmission rate!
 - (Almost) anything can be proven with a large enough dataset
 - Need to distinguish "meaningful" from significant
 - Make enough comparisons and something will be "statistically" significant
 - 1 of any 20 random comparisons will, by definition be "significant" with an alpha = 0.05

Privacy and Security is Essential

Extortion Plot Threatens to Divulge Millions of Patients' Prescriptions

By David Kravets ☑ November 06, 2008 | 6:48:54 PM Categories: Breaches

A St. Louis company managing prescription benefits of 50 million people said Thursday it called the FBI to investigate an extortion plot threatening to expose personal information, including prescriptions, of millions of its clients.



Express Scripts said it has received an

anonymous letter containing the names of some 75 clients that includes dates of birth, Social Security numbers and their prescriptions. The letter threatens to expose millions of patient records if Express Scripts does not pay an undisclosed amount of money.

"We are cooperating with the FBI and are committed to doing what we can to protect our members' personal information and to track down the person or persons responsible for this criminal act," George Paz, the company's president, said in a statement.

Paz added that, "as security experts know, no data system is completely invulnerable."

Of course, this needs to be balanced with...

Mass. General paperwork for 66 patients lost on Red Line train

Personal, billing data are missing

By Milton J. Valencia, Globe Staff | March 24, 2009

And...

- One in five Americans report that they or a family member have experienced a medical error
- Conservatively, medical errors are the 8th leading cause of death in the US with 44-98,000 deaths per annum
- 195,000 people in the USA die each year because of potentially preventable, in-hospital medical complications




Healthcare Data Analytics

Principles of Secondary Health Data Analytics

- Patient focus for all data activities
 - All uses should benefit patients
 - Minimal disclosure of data to meet need
 - Never allow re-identification of patients
- Data uses must be transparent
 - overseen by honest brokers or stewards
 - everyone in the process is a data steward
- Data must be collected THROUGH the process of care, not in addition to it
- Data analytics for analysis of outcomes, value and comparative effectiveness must be the goal. This will require:
 - new data architectures
 - new expertise for experts in data visualization and predictive analytics
 - new training for others in understanding the output of these efforts


Extracted data from EHR systems to develop a complete view of patient care



* EHR= Electronic Health Record, including contributing reporting systems ** RVU = Relative Value Unit 17 | © 2009 Humedica, Inc. All rights reserved.

Health Data Integration Framework


Program Stewardship



ACO Target Improvement: Two Components

1. Exception management

- a. Identify potential physician or patient "outliers"
 - · Clinical intuition
 - Population analytics—patterns of risk/cost
- b. Enables individualized patient attention




19 © 2009 Humedica, Inc. All rights reserved.

Improvement: Two Components

1. Exception management

- a. Identify potential physician or patient "outliers"
 - Clinical intuition
 - Population analytics—patterns of risk/cost
- b. Enables individualized patient attention



Overall Cost of Care

20 © 2009 Humedica, Inc. All rights reserved.

Preventable Hospitalizations – Key Focus

• \$30.8 Billion – Preventable admissions

 \$1 in \$10 hospital dollars spent could be prevented by better ambulatory care and/or patient self-care


• Diabetes:

Clinical Condition (HCUP data, 2006)	Total Number of Hospital Admissions (in 000)	Number of Admissions per 100,000 Population	Total Hospital Costs (in 000,000)
Uncontrolled DM without Complications	49	22	\$227
Short Term Complications: Ketoacidosis, Hyperosmolarity, Coma	133	59	\$904
Long Term Complications: Renal, Ophthalmologic, Neurological, Circulatory	295	131	\$2,990
DM-related Lower Extremity Amputations	83	37	\$1,636


Quickly Identify Opportunities Within Your Population

• 1 • HU	MEDICA	User: ag_did@humedica.com	Log Õut		
Mine	edShare [™] Ambulatory Home Reports Workspace		2		
Create,	View, and Edit Graphs	Add Grap	oh 🖽		
Graph 1					
		Show Data	Actions +		
Percent Conditio	of Pts w DM-Related Hosp Admit [In Time Period] by DM-Related in Categories [Up to End of Time Period]		e/Load		
		Disease Cohort: Diabetes Mellitus 🖵			
		🗭 Add criteria 🙊 Cli	earall		
100%		Time Devied			
Percent of Pis w DM-Related Hosp Admit (In Time Period) % 0.0 % 0.0 %	9	Time Period Lime period: Last Full Year +			
튼 필 80%	Identify				
upy dso	Performance	Filters (2 active)			
elated H		AND			
8-WQ 60%	Variance with	Ref Current1			
it of Pts	Comparative Data				
Percer		🕀 Add 😪 Cle	ear all		
40 %		Graph Settings			
		Standard Charts Scatter Plot Parallel Plot			
20%					
		Show (Y-Axis): Pts w DM-Related Hosp A Percent of 💗			
		By (X-Axis): DM-Related Condition C			
Į		Compare by: None			
	Any Any Renal Any Depression Any Hypoglycemi Any Skin and Diabetic Hypoglycemi Cardiovascul Condition of Neurologic Ophthalmol a Musculoukel Ketoacidosis a or ar Condition Interest Condition of ogic etal or Ketoacidosis	✓ Show benchmark			
		Chart type:			
NOTIFICATION	5: Y DM-Pelated Condition Categories [Up to End of Time Period]				
	Suid: 601 revision 17452.				

Specific Clinical Comparisons Available Nowhere Else



Explore & Identify Clinical Drivers




The Evidence

- In patients with diabetes and renal disease, lowering blood pressure and the levels of urinary albumin are effective in reducing the risk of end-stage renal disease as well as that of myocardial infarction, heart failure, and stroke.
- ACE inhibitors and ARBs appear to be the most effective anti-hypertensive agents.

New England Journal of Medicine 351;19 (November 4, 2004)

Quantify the Addressable Clinical Opportunities



Identify Variance by Clinic

	Humedica	+							1
ним			Ца	ome Re	eports	Workspace		User: ag	did@humedica.com Log Cut
		Ambulatory		nie ne	ports	wonspace	_		0 2
ate, V	iew, and	Edit Graphs							Add Graph
aph 1									
									Show Data Actions 🔻
Rate of Pt. Frequent)	s w Amb Rx for [In Time Period	ACEI/ARB [In Time Pe	riod] by Primary Clinic	(Most				Cohort	Save/Load
								Disease Cohort: Diabetes Melitus 👻	
								Add criteria	🕱 Clear all
102%								+ Judi circena	X Clearai
								Time Period	
								Time period: Last Full Year	
80%								Filters (4 active)	
								Age [Current]	
								INCLUDE values 18 to 75	
60%	-	-		-				INCLUDE values: Type 2	
								Value. True	
								😤 🛲 Pts w Diabetes with Renal Complications [U Value: Tue	pto En.,
40%									
								4 Add	🕱 Clearall
								Graph Settings	
20%								Standard Charts Scatter Plot Parallel Plot	
								Standard Charts Scotter not Fundher not	
								Show (Y-Axis): Pts w Amb Rx for ACEI/A Rate of	
	FAC21	FAC16	EAC4	FAC2	FAC20	F.AC9	FAC15	By (X-Axis): Primary Clinic (Most Freq	
								Compare by: None	
	_		Primary Cli	inic (Most Frequent) ((In Time Period)			Show benchmark	
ICATIONS:	-							—	2010 Humedica, Inc. All rights reserv

... Or by Physician

Humedica	+				T		
• HUMEDIC	:A			Usen ag_did@hum	edica.com Log Out		
MinedShare	™ Ambulatory	Home Report:	Workspace		0 L		
Create, View, an	Create, View, and Edit Graphs						
				,			
Graph 1							
				Hde	Data Actions 🔻		
Rate of Pts w Amb [Current]	Rx for ACEI/ARB [In Time Peri	iod] by PCP		Cohort	Save/Load		
Icurrentj				Disease Cohort: Diabetes Mellitus 👻			
ğ							
100%							
ров 100% 100% в 20% 20% 20% 20% 20% 20% 20% 20% 20% 20%				🗭 Add criteria	😭 Clear al		
80%							
				Time Period			
v⊊ 2 60%				Time period: 🗌 Last Full Year 👻			
w.Arr							
E 40%				Filters (5 active)			
				🔗 🙃 Age [Current]			
				NCLUDE values 18 to 75	=		
20%				DM Type [Ever] NCI UDE values: Type 2			
				🙊 🙃 Pts w Hypertension [Up to End of Time Period]			
	es es	e 5	6 6 A	AND Value: True			
den.	hr hr	19 p.	the the the	😥 🧓 Pts w Diabetes with Renal Complications [Up to En			
				Value: True			
		PCP [Current]		For DM Pts Assigned to Pt's PCP [Current] [In Time NCLUD[values 300 to 1111			
NOTIFICATIONS: Y							
Data Patient List G	Graph Notes		R. a				
				- • • • • • • • • • • • • • • • • • • •	😧 Clear al		
PCP (Current) Graph			·	Graph Settings			
MARSHALL, WYATT MD WEBSTER MALCOLM MD	A9 80.6 29 36 A15 72.2 13 18						
	A16 72.2 13 18 A23 50.0 9 18			Standard Charts Scatter Plot Parallel Plot			
SPENCE, CAMILLE MD	A3 85.7 12 14						
	A17 71.4 10 14			Show (Y-Axis): Pts w Amb Rc for ACEI/A Rate of 🚽			
VELAZQUEZ,NORBERT MC	A4 92.3 12 13			By (X-Axis): PCP [Current]			
	A13 70.0 7 10 A19 60.0 6 10						
WIGGINS CLIETON MD				Compare by: None	•		
Build: 604 revision: 17457				Հայացին (ե.) 2008-2010 Hame	dica, Inc. All rights reserved.		
Transferring data from demo03	8 humedica net				Α 4		


🗎 //,

Pharma Marketing Questions Answerable with EHR Data

Group	Outstanding Questions	EHR Data-Based Solution
Patients	How is my brand being used (clinically) relative to competitive products?	Brand-level comparison of patient's clinical profile at treatment initiation and follow-up
Physicians	What are the drivers of physician prescribing behavior?	Natural language processing to derive insight from physician notes, including physician treatment rationale
Hospitals	How are hospital stays benefiting or disrupting brand use?	Analyze patient flow (i.e., in and out of hospital) and corresponding treatment patterns with longitudinal clinical data
Payers	How is the hospital formulary and/ or PBM formulary influencing the <i>clinical</i> adoption of brands?	Link patients' clinical profiles with insurance coverage to determine formulary's influence on clinical practice (i.e., treatment initiation) and leverage data to inform negotiations with key payers


Lab, Radiology and Pathology Data Allows You to Visualize Patient Outcomes

Pre vs. Post LDL Results by Brand and Line of Therapy




Understand Rationale Behind Treatment Changes

Distribution of Switching Rationale: Dyslipidemia




Compare "Real-world" Clinical Practice to Established **Treatment Protocols**

Although the ADA recommends Basal Insulin as a first-line add-on to metformin when HbA1c is at or above 7 g/dL, Lantus and Levemir are prescribed at higher median HbA1c levels when compared to other medications, including other injectables.




HbA1c > 7 g/dL



Median HbA1c at Therapeutic Initiation

Understand How Payers Influence Clinical Practice

HbA1c at Brand Initiation



- Understand and track how formularies influence clinical practice
- Clear understanding of your product's initiation level by payer category
 - Ability to link patient's clinical profile (i.e. lab values, prescriptions, etc) with insurance coverage information


© 2009 Humedica, Inc. All rights reserved. trends)





Directions: Data Visualization


243345098543534353

Data Mining: Creating Value from Healthcare Data











- Data Visualization
- Predictive Analytics
- Network and Clustering Analysis
- Geographical Analysis (GIS)


35 © 2009 Humedica, Inc. All rights reserved.




HbA1c vs. LDL Scatterplot: Clinic 02 vs. 01




Comorbidities by Site and Diabetes Status



Diabetes Prescribing Patterns



Primary Care Physicians for Diabetes Patients



Clinic 01 - blue Clinic 02 - red

- Clinic 03 cyan Clinic 04 - green Clinic 05 - grey Clinic 07 - yellow Clinic 08 - orange Clinic 10 - violet
- Clinic 11 magenta

Type 2 Diabetes Patients

Diamond – 1º care MD Hexagon – Endocrinologist

Clinic 01 - blue Clinic 02 - red

Clinic 03 - cyan Clinic 04 - green Clinic 05 - grey Clinic 07 - yellow Clinic 08 - orange Clinic 10 - violet Clinic 11 – magenta

41 © 2009 Humedica, Inc. All rights reserved.



Conclusions

- Secondary use of data has significant value for many stakeholders
- EHR adoption and improvements make this data available today
- NLP will remain an important source of data for the foreseeable future
- Secondary data must be managed carefully to prevent disclosure of private information
- Data visualization provides powerful insights, but requires a mindset and skills that are often not (yet) available in end users